发明授权
US06916827B2 Substituted ring-fused imidazole derivative: GABAA receptors ligands
失效
取代的环稠合咪唑衍生物:GABA A受体配体
- 专利标题: Substituted ring-fused imidazole derivative: GABAA receptors ligands
- 专利标题(中): 取代的环稠合咪唑衍生物:GABA A受体配体
-
申请号: US10438496申请日: 2003-05-15
-
公开(公告)号: US06916827B2公开(公告)日: 2005-07-12
- 发明人: George D. Maynard , Jun Yuan , George P. Luke , Kevin Currie
- 申请人: George D. Maynard , Jun Yuan , George P. Luke , Kevin Currie
- 申请人地址: US CT Branford
- 专利权人: Neurogen Corporation
- 当前专利权人: Neurogen Corporation
- 当前专利权人地址: US CT Branford
- 代理机构: McDonnell Boehnen Hulbert & Berghoff LLP
- 主分类号: A61P25/00
- IPC分类号: A61P25/00 ; C07D471/04 ; A61K31/437 ; A61K31/4184 ; A61K31/506 ; C07D403/06
摘要:
Substituted ring-fused imidazole derivatives that bind to GABAA receptors are provided. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).
公开/授权文献
信息查询